Search
Blog Post
Women in Science: Emese Zsiros MD, PhD
… Women in Science: Emese Zsiros MD, PhD Emese Zsiros, MD, PhD , grew up in Budapest, Hungary, with two … medical professionals play in peoples’ lives,” says Dr. Zsiros. After earning a combined MD/PhD at a top medical … Emese Zsiros, MD, PhD , grew up in Budapest, Hungary, with two …
Blog Post
Cancer Innovations: Prioritizing quality of life while treating cancer
… the Cell Stress and Biophysical Therapy Program, and Emese Zsiros, MD, PhD, FACOG , Director of Research in the … more — and better quality — time with their loved ones Dr. Zsiros has spent the past several years researching the use … was 8-15%. The combination has a synergistic effect,” Dr. Zsiros says. “The typical treatments for ovarian cancer …
Blog Post
Cancer Innovations: New initiative reduced prescribed opioids by 45%
… recovery. How would patients fare without opioids? Emese Zsiros, MD, PhD, FACOG, a gynecologic oncologist at Roswell … based on their clinical experience. The results? Dr. Zsiros says the number of opioids prescribed to these … in the fight against the ongoing opioid epidemic.” Dr. Zsiros and her team reported the results from the first six …
Clinical Trial
A Phase I First-In-Human, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
… SIM0505 in Adult Participants with Advanced Solid Tumors I Zsiros, Emese This is an open-label, multicenter phase 1 …
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
… MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS I Zsiros, Emese This is an open-label, phase 1, dose escalation …
Clinical Trial
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
… in Patients with Platinum Resistant Ovarian Cancer III Zsiros, Emese This phase 3 study will be conducted in …
Clinical Trial
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer
… CDX-1140 in Patients with Recurrent Ovarian Cancer II Zsiros, Emese This phase II trial tests whether pembrolizumab …
Blog Post
Coping with hair loss: Jerrolynn's story
… oncologists Katherine LaVigne Mager, MD, FACOG and Emese Zsiros, MD, PhD, FACOG. “Dr. Mager is a godsend and Dr. Zsiros was my first doctor here and integral in discovering … oncologists Katherine LaVigne Mager, MD, FACOG and Emese Zsiros, MD, PhD, FACOG. “Dr. Mager is a godsend and Dr. …
Clinical Trial
Randomized Phase 2 Trial of APL-2 with Pembrolizumab vs. APL-2 with Pembrolizumab and Bevacizumab vs. Bevacizumab alone in Patients with Recurrent Ovarian Cancer and Persistent Malignant Effusion
… Ovarian Cancer and Persistent Malignant Effusion II Zsiros, Emese This phase II trial studies the effect of APL-2 …
Clinical Trial
A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer ( 27T51-01)
… primary peritoneal, or fallopian tube cancer ( 27T51-01) I Zsiros, Emese This study is researching an experimental CAR T …